NCT06216665 Effect of Pulsatile Hormone Administration on Insulin Action
| NCT ID | NCT06216665 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pennington Biomedical Research Center |
| Condition | Insulin Sensitivity |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2024-03-04 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2024-03-04 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In humans, insulin is secreted in pulses from the pancreatic beta-cells, and these oscillations help to maintain fasting plasma glucose levels within a narrow normal range. Given the fluctuations in insulin concentrations, oscillations enhance precision of control. The hyperinsulinemic euglycemic clamp test (clamp) involves a continuous infusion of insulin and is the gold standard for measuring insulin sensitivity. In this study, insulin sensitivity measured using the standard clamp will be compared with a clamp in which the same total amount of insulin as the standard clamp is infused every five minutes instead of continuously.
Eligibility Criteria
Inclusion Criteria: * Completion of the Motivate Study (NCT05649176) Exclusion Criteria: * Non-completion of the end-of-study hyperinsulinemic euglycemic clamp test of the Motivate study
Contact & Investigator
Candida Rebello, PhD
PRINCIPAL INVESTIGATOR
Pennington Biomedical Research Center
Frequently Asked Questions
Who can join the NCT06216665 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Insulin Sensitivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06216665 currently recruiting?
Yes, NCT06216665 is actively recruiting participants. Contact the research team at Candida.Rebello@pbrc.edu for enrollment information.
Where is the NCT06216665 trial being conducted?
This trial is being conducted at Baton Rouge, United States.
Who is sponsoring the NCT06216665 clinical trial?
NCT06216665 is sponsored by Pennington Biomedical Research Center. The principal investigator is Candida Rebello, PhD at Pennington Biomedical Research Center. The trial plans to enroll 12 participants.